Real-World Status of Medical Care and Treatment of Chronic Obstructive Pulmonary Disease by Respiratory Specialists in Japan

Shu Hashimoto, Ryoko Sorimachi, Naoyuki Makita, Naoki Tashiro, Satoko Sugaya, Yoshifumi Arita, Masakazu Ichinose, Shu Hashimoto, Ryoko Sorimachi, Naoyuki Makita, Naoki Tashiro, Satoko Sugaya, Yoshifumi Arita, Masakazu Ichinose

Abstract

Introduction: The ACO Registry Study was a multicenter, prospective, observational cohort study aiming to clarify the situation of asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) within the COPD population using the Japanese Respiratory Society (JRS) criteria. We reported the proportion of patients who met the ACO criteria among the COPD population at study registration.

Methods: Using data collected at registration, we investigated the implementation of each diagnostic examination/test required for ACO diagnosis in the full analysis set. Among patients with data necessary for ACO diagnosis, ACO/non-ACO patients with/without asthma diagnosed by a physician and proportions of inhaled corticosteroid (ICS) treatments for COPD were calculated.

Results: Of 708 patients analyzed, 396 (55.9%) had the data necessary for ACO diagnosis, and 312 (44.1%) did not. The proportions of patients who underwent laboratory and respiratory function tests (peripheral blood eosinophil count [79.8%], fractional exhaled nitric oxide [63.7%], airway reversibility [46.8%], and total immunoglobulin [Ig] E/specific IgE [33.3%]) were lower than those who underwent subjective examinations (perennial allergic rhinitis [100%], asthma before age 40 years [97.2%], and variable/paroxysmal respiratory symptoms [94.5%]). Among patients with the data necessary for ACO diagnosis and without asthma complications according to the physician's diagnosis, 15.1% (33/219) met the ACO criteria. Of patients who met the ACO criteria, 74.3% (75/101) received ICS, and 25.7% (26/101) did not. By comparison, among patients who did not meet the ACO criteria, 35.6% (105/295) were receiving ICS, and 64.4% (190/295) were not.

Conclusions: The proportion of objective laboratory and physiological tests was lower than expected, despite study sites having the clinical resources for objective tests. Most ACO patients were being treated with ICS as recommended in the JRS treatment guidelines. Attempts should be made to further increase the proper use of ICS among these patients in Japan.

Trial registration: ClinicalTrials.gov, NCT03577795.

Keywords: Asthma–COPD overlap; Blood eosinophil count; Chronic obstructive pulmonary disease; Fractional exhaled nitric oxide; Immunoglobulin E; Inhaled corticosteroid.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Summary of patient disposition within the study
Fig. 2
Fig. 2
Proportions of patients who underwent evaluation for each ACO diagnostic criterion among overall patients (full analysis set, N = 708), patients with data necessary for ACO diagnosis (n = 396), and patients lacking the data necessary for ACO diagnosis (n = 312). ACO asthma–COPD overlap, COPD chronic obstructive pulmonary disease, CT computed tomography, FeNO fractional exhaled nitric oxide, Ig immunoglobulin, LAA low attenuation areas

References

    1. World Health Organization. Chronic obstructive pulmonary disease (COPD). Key Facts. June 2021. . Accessed Oct 1, 2021.
    1. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom. 2018;3:e4. doi: 10.1017/gheg.2018.1.
    1. Yanagisawa S, Ichinose M. Definition and diagnosis of asthma–COPD overlap (ACO) Allergol Int. 2018;67:172–178. doi: 10.1016/j.alit.2018.01.002.
    1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2021. . Accessed Oct 1, 2021.
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Reported 2021. . Accessed Oct 1, 2021.
    1. The Japanese Respiratory Society . Guidelines for diagnosis and treatment of COPD (chronic obstructive pulmonary disease) 5. Tokyo: Medical Review; 2018.
    1. Milewska A, Rysiak E, Zareba I, Holownia A, Mroz RM. Costs of treatment of chronic obstructive pulmonary disease. Adv Exp Med Biol. 2016;885:67–75. doi: 10.1007/5584_2015_199.
    1. The Japanese Respiratory Society . The JRS guidelines for the management of ACO 2018. Tokyo: Medical Review; 2017.
    1. Hashimoto S, Sorimachi R, Jinnai T, Ichinose M. Asthma and chronic obstructive pulmonary disease overlap according to the Japanese Respiratory Society diagnostic criteria: the prospective, observational ACO Japan cohort study. Adv Ther. 2021;38:1168–1184. doi: 10.1007/s12325-020-01573-x.
    1. Cosio BG, Soriano JB, López-Campos JL, et al. Defining the asthma–COPD overlap syndrome in a COPD cohort. Chest. 2016;149:45–52. doi: 10.1378/chest.15-1055.
    1. Tamada T, Sugiura H, Takahashi T, et al. Biomarker based detection of asthma–COPD overlap syndrome in COPD populations. Int J Chron Obstruct Pulmon Dis. 2015;10:2169–2176. doi: 10.2147/COPD.S88274.
    1. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44–52. doi: 10.1164/rccm.201106-0992OC.
    1. Yamamura K, Hara J, Kobayashi T, et al. The prevalence and clinical features of asthma–COPD overlap (ACO) definitively diagnosed according to the Japanese Respiratory Society Guidelines for the Management of ACO 2018. J Med Invest. 2019;66:157–164. doi: 10.2152/jmi.66.157.
    1. Toyota H, Sugimoto N, Kobayashi K, et al. Comprehensive analysis of allergen-specific IgE in COPD: mite-specific IgE specifically related to the diagnosis of asthma–COPD overlap. Allergy Asthma Clin Immunol. 2021;17:13. doi: 10.1186/s13223-021-00514-9.
    1. Kyogoku Y, Sugiura H, Ichikawa T, et al. Nitrosative stress in patients with asthma–chronic obstructive pulmonary disease overlap. J Allergy Clin Immunol. 2019;144:972–83.e14. doi: 10.1016/j.jaci.2019.04.023.
    1. Mekov E, Nuñez A, Sin DD, et al. Update on asthma–COPD overlap (ACO): a narrative review. Int J Chron Obstruct Pulmon Dis. 2021;16:1783–1799. doi: 10.2147/COPD.S312560.
    1. Takayama Y, Ohnishi H, Ogasawara F, Oyama K, Kubota T, Yokoyama A. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma–COPD overlap. Int J Chron Obstruct Pulmon Dis. 2018;13:2525–2532. doi: 10.2147/COPD.S167600.
    1. Ichinose M, Fukushima Y, Inoue Y, et al. Efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD: a subgroup analysis of the KRONOS Study. Int J Chron Obstruct Pulmon Dis. 2019;14:2979–2991. doi: 10.2147/COPD.S220850.
    1. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747–758. doi: 10.1016/S2213-2600(18)30327-8.
    1. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi: 10.1056/NEJMoa1916046.
    1. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680. doi: 10.1056/NEJMoa1713901.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner